undamentalytics Newsletter
Sign in

Zevra Therapeutics, Inc. balance sheet

At the end of fiscal 2025, Zevra Therapeutics, Inc. had total assets of $285m, total liabilities of $130m and shareholders' equity of $155m. It held $62.4m in cash against $63.6m of debt: net debt of $1.2m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents21032183411265433462145
Receivables———0221716102322
Inventory———————10222
Total current assets—10542478115938786223251
Goodwill———————05555
Total assets—1455271111133115172178285303
Accounts payable—214111414132—
Total current liabilities—48125841274343949
Long-term debt—7781776800560620
Total debt0898380680134362640
Total liabilities—386593857864011013813085
Shareholders' equity−24−49−10−67−74−66102756240155218
Non-controlling interests and other (assets − liabilities − equity)—24————25—————
Net debt (negative = net cash)−2−3−24657764−112−53−0281−145
Shares outstanding————2m5m35m35m42m54m57m59m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: NAII vs ZVRANAGE vs ZVRAHRTX vs ZVRAETON vs ZVRA

More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies

Figures from Zevra Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Zevra Therapeutics, Inc.